Halozyme Therapeutics Analyst Ratings
What 13 Analyst Ratings Have To Say About Halozyme Therapeutics
Halozyme Therapeutics Analyst Ratings
Halozyme Therapeutics Analyst Ratings
Halozyme Therapeutics Analyst Ratings
Wells Fargo Adjusts Price Target on Halozyme Therapeutics to $58 From $48, Maintains Overweight Rating
Halozyme Downgraded at Piper Sandler Despite Guidance Raise
Halozyme Therapeutics Analyst Ratings
Halozyme Therapeutics Analyst Ratings
Halozyme Therapeutics Analyst Ratings
Halozyme Therapeutics Analyst Ratings
JMP Securities Maintains Market Outperform on Halozyme Therapeutics, Lowers Price Target to $71
Halozyme Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Halozyme Therapeutics, Maintains $50 Price Target
Halozyme Therapeutics Analyst Ratings
Halozyme Therapeutics Analyst Ratings
Halozyme Therapeutics Analyst Ratings
Halozyme Therapeutics Analyst Ratings
TD Cowen Reaffirms Their Buy Rating on Halozyme (HALO)
Halozyme Therapeutics Analyst Ratings